Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prabotulinumtoxin A - Daewoong Pharmaceuticals

Next Previous
Drug Profile

Prabotulinumtoxin A - Daewoong Pharmaceuticals

Alternative Names: ABP 450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva; Onabotulinumtoxin A biosimilar - Daewoong Pharmaceuticals; Prabotulinumtoxin A; PrabotulinumtoxinA-xvfs

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer AEON Biopharma; Daewoong Pharmaceutical; Evolus
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Antispastics; Anxiolytics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Gastrokinetics; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines
  • Phase III Hypertrophy; Muscle spasticity; Torticollis
  • Phase II/III Blepharospasm; Facial wrinkles
  • Phase II Migraine
  • Phase I Gastroparesis
  • Preclinical Post-traumatic stress disorders

Most Recent Events

  • 26 Aug 2026 Daewoong Pharmaceutical plans a phase III trial for Glabellar lines (IM), in January 2027 (NCT07783763)
  • 13 Aug 2026 AEON Biopharma expects receipt of additional FDA feedback from its planned BPD Type 2b interaction in second half of 2026
  • 25 Mar 2026 AEON Biopharma plans to hold a Biosimilar Biological Product Development (BPD) Type 2b meeting with US FDA for Prabotulinumtoxin A in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top